Chronic spontaneous urticaria
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
InflaRx reports positive phase 2 results for HS and CSU treatments
Topline results demonstrated treatment efficacy for both conditions
Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria
More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease
Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m
The common skin condition affects approximately 40 million people worldwide
UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults
The inflammatory skin disease affects approximately one in every 100 people in the US
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
The inflammatory skin disease affects about 1% of the population in most studied countries
Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria
Detailed results from the confirmatory trial will be submitted to the FDA later this year
Acelyrin shares positive phase 3 results for izokibep in hidradenitis suppurativa
Despite the promising readout, the company said it will not be moving forward with the candidate in the inflammatory skin condition
UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults
The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy
UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults
The regulator’s decision marks Bimzelx’s fourth approved indication within the EU
UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults
The inflammatory skin disease affects an estimated 1% of the population in most studied countries